Last reviewed 2026-04-23 · How we verify

Mineralocorticoid receptor antagonist potassium-canrenoate

Mineralocorticoid receptor antagonist potassium-canrenoate is a Mineralocorticoid receptor antagonist Small molecule drug developed by University College, London. It is currently in Phase 3 development for Heart failure, Hypertension, Primary aldosteronism.

Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention.

Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention. Used for Heart failure, Hypertension, Primary aldosteronism.

At a glance

Mechanism of action

As a mineralocorticoid receptor antagonist, potassium-canrenoate inhibits the binding of aldosterone to its receptor in the collecting duct of the nephron. This prevents sodium reabsorption and potassium wasting, leading to increased sodium and water excretion while conserving potassium. The drug is used primarily in conditions characterized by aldosterone excess or where aldosterone antagonism provides therapeutic benefit, such as heart failure and hypertension.

Approved indications

• Heart failure
• Hypertension
• Primary aldosteronism

Common side effects

• Hyperkalemia
• Gynecomastia
• Menstrual irregularities
• Gastrointestinal disturbances

Key clinical trials

• Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
• Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19. (PHASE4)
• Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance (PHASE2, PHASE3)
• Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mineralocorticoid receptor antagonist potassium-canrenoate CI brief — competitive landscape report
• Mineralocorticoid receptor antagonist potassium-canrenoate updates RSS · CI watch RSS
• University College, London portfolio CI

Frequently asked questions about Mineralocorticoid receptor antagonist potassium-canrenoate

Related

• Drug class: All Mineralocorticoid receptor antagonist drugs
• Target: All drugs targeting Mineralocorticoid receptor (MR)
• Manufacturer: University College, London — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Heart failure
• Indication: Drugs for Hypertension
• Indication: Drugs for Primary aldosteronism
• Compare: Mineralocorticoid receptor antagonist potassium-canrenoate vs similar drugs
• Pricing: Mineralocorticoid receptor antagonist potassium-canrenoate cost, discount & access